When compared to low expression of ST3GAL2, patients with high expression of ST3GAL2 were at higher risk for multiple tumors (OR: 3.22, 95% CI: 1.46–7.13), moderately and poorly differentiated tumor (OR: 2.66, 95% CI: 1.28–5.53) and relapse (OR: 2.13, 95% CI: 1.02–4.45). Here, ST3GAL2 is linked to neoplasm.